Back to top
more

CONMED (CNMD)

(Real Time Quote from BATS)

$72.10 USD

72.10
129,660

-1.86 (-2.52%)

Updated Aug 30, 2024 01:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 26% (185 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Quest Diagnostics (DGX) Partners to Offer New Testing Service

by Zacks Equity Research

Quest Diagnostics' (DGX) latest test indicates how different genes and their variants affect how a person reacts to drugs.

Here's Why You Should Buy Boston Scientific (BSX) Stock

by Zacks Equity Research

Investors are optimistic about Boston Scientific's (BSX) strong improvement in organic sales, indicating a solid rebound in the legacy business.

Are You Looking for a Top Momentum Pick? Why Conmed (CNMD) is a Great Choice

by Zacks Equity Research

Does Conmed (CNMD) have what it takes to be a top stock pick for momentum investors? Let's find out.

IDEXX (IDXX) Stock Up 18.4% YTD: Will the Rally Continue?

by Zacks Equity Research

The continued solid demand for veterinary services and benefits from strong execution poise IDEXX (IDXX) well for future growth.

Hologic (HOLX) Gains From Core Businesses' Growth, Innovation

by Zacks Equity Research

Hologic's (HOLX) GYN Surgical business grows organically as the company registers procedural volumes return and acceleration from new business lines.

Reasons to Retain Cardinal Health (CAH) in Your Portfolio

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

CONMED (CNMD) Stock Hits 52-Week High: Will It Continue?

by Zacks Equity Research

CONMED (CNMD) continues to raise optimism in investors due to its broad product spectrum.

IDEXX (IDXX) Launches First Veterinary Diagnostic Test

by Zacks Equity Research

IDEXX's (IDXX) Cystatin B Test can help veterinary professionals to spot kidney damage before it affects kidney function, which may result in better patient outcomes.

Here's Why You Should Invest in Hologic (HOLX) Stock Now

by Zacks Equity Research

Investors are optimistic about Hologic (HOLX) on continued strength in GYN Surgical and Breast Health businesses.

Masimo (MASI) Inks Deals for Patient Monitoring Technologies

by Zacks Equity Research

Masimo's (MASI) advanced monitoring technologies and solutions attract new customers looking for better patient care, using remote and centralized surveillance, and seamless data transfer to EMRs.

NextGen (NXGN) Expands Partnership With Large Urology Group

by Zacks Equity Research

NextGen's (NXGN) cloud-based healthcare technology solution, Enterprise EHR, is selected by Associated Urologists of North Carolina to create an integrated platform, especially for urology-specific workflows.

Reasons to Add West Pharmaceutical (WST) to Your Portfolio Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Cooper Companies (COO) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Cooper Companies' (COO) second-quarter fiscal 2023 revenues reflect a solid segmental performance despite a year-over-year decline in earnings.

PDCO or CNMD: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PDCO vs. CNMD: Which Stock Is the Better Value Option?

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Reasons to Retain Cardinal Health (CAH) in Your Portfolio

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

Here's Why You Should Retain Veradigm (MDRX) Stock for Now

by Zacks Equity Research

Veradigm (MDRX) continues to hold on to investors' interests owing to its strategic alliances.

Why You Should Buy The Cooper Companies (COO) Stock Now

by Zacks Equity Research

The Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to drive the top line further.

CONMED (CNMD) Beats on Q1 Earnings, Ups '23 EPS View

by Zacks Equity Research

CONMED's (CNMD) adjusted first-quarter sales and earnings recover from the disruption in the fourth quarter due to implementation of a new warehouse management system.

Conmed (CNMD) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Conmed (CNMD) delivered earnings and revenue surprises of 10% and 10.54%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Indrajit Bandyopadhyay headshot

MedTech Stocks' Q1 Earnings Due on Apr 26: MMSI, CNMD & More

by Indrajit Bandyopadhyay

Medical Device players are expected to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how MMSI, CNMD, NVRO and ARAY are likely to have performed this time.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about CONMED (CNMD), owing to its broad product spectrum.

CONMED (CNMD) Down on Q4 Earnings Miss, New System Hurts Sales

by Zacks Equity Research

CONMED's (CNMD) adjusted fourth-quarter sales and earnings reflect disruption due to implementation of a new warehouse management system.

Conmed (CNMD) Lags Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Conmed (CNMD) delivered earnings and revenue surprises of -54.84% and 18.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?